Bo Zhou
About Bo Zhou
Bo Zhou is an Associate Director at Deciphera Pharmaceuticals, specializing in gene therapy discovery with expertise in CRISPR-Cas 9 Pool Screening. He has over 15 years of experience in immune-oncology and has held various roles in research and clinical settings.
Work at Deciphera Pharmaceuticals
Bo Zhou has been serving as Associate Director at Deciphera Pharmaceuticals since 2023. The role is based in Wayne, Pennsylvania, and is conducted remotely. In this position, Zhou contributes to the company's efforts in drug development and translational research, leveraging extensive experience in the immune-oncology field.
Previous Experience in Clinical Research
Before joining Deciphera Pharmaceuticals, Bo Zhou worked as a Clinical Scientist at MEI Pharma from 2022 to 2023. This role was also remote and located in the San Diego Metropolitan Area. Zhou has a history of collaboration with Contract Research Organizations (CROs) and academic institutions, enhancing study management and execution.
Education and Expertise
Bo Zhou holds a Master's degree in Medicine from Xi'an Jiaotong University, obtained from 2000 to 2003. Zhou furthered education by earning a Doctor of Philosophy (PhD) in Medicine from Shinshu University between 2003 and 2007. Zhou is recognized for expertise in CRISPR-Cas 9 Pool Screening, model development, and target validations in gene therapy discovery.
Background in Pediatric Medicine
Zhou began a career in medicine as a Pediatrician at Xi'an Jiaotong University from 1998 to 2002. This early experience laid the foundation for a diverse career in medical research and clinical development, transitioning into roles that focus on translational research and drug development.
Achievements in Translational Research
Throughout a career spanning over 15 years in the immune-oncology field, Bo Zhou has played a significant role in supporting rare disease studies. Zhou has established biomarker strategies and developed preclinical data sets to aid in patient stratification and the exploration of novel therapeutic combinations.